TWST:NSD-Twist Bioscience Corp (USD)

COMMON STOCK | Diagnostics & Research |

Last Closing

USD 48.9

Change

+0.78 (+1.62)%

Market Cap

USD 2.85B

Volume

0.22M

Analyst Target

USD 75.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-24 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
IDXX IDEXX Laboratories Inc

+0.46 (+0.11%)

USD 35.79B
ILMN Illumina Inc

+0.22 (+0.16%)

USD 23.01B
NTRA Natera Inc

+0.40 (+0.25%)

USD 22.06B
ICLR ICON PLC

+3.24 (+1.54%)

USD 17.95B
EXAS EXACT Sciences Corporation

-0.82 (-1.39%)

USD 11.56B
MEDP Medpace Holdings Inc

+3.64 (+1.07%)

USD 10.75B
RDNT RadNet Inc

+0.74 (+1.02%)

USD 6.04B
GH Guardant Health Inc

+0.53 (+1.71%)

USD 3.91B
SHC Sotera Health Co

+0.22 (+1.65%)

USD 3.72B
VCYT Veracyte Inc

+0.19 (+0.46%)

USD 3.42B

ETFs Containing TWST

ARKG ARK Genomic Revolution ET.. 9.41 % 0.75 %

+0.21 (+1.34%)

USD 1.04B
ARCG:LSE ARK Genomic Revolution UC.. 8.78 % 0.00 %

+3.98 (+1.34%)

USD 4.85M
ARKG:LSE ARK Genomic Revolution UC.. 8.78 % 0.00 %

+0.06 (+1.34%)

USD 4.85M
EDOC:SW Global X Telemedicine & D.. 4.25 % 0.00 %

N/A

N/A
WDNA:LSE WisdomTree BioRevolution .. 4.11 % 0.00 %

+0.12 (+1.34%)

N/A
WRNA:XETRA WisdomTree BioRevolution .. 3.48 % 0.00 %

N/A

USD 2.77M
WDNA WisdomTree BioRevolution .. 3.43 % 0.00 %

+0.05 (+1.34%)

USD 2.41M
WBIO:LSE WisdomTree BioRevolution .. 3.42 % 0.00 %

+8.80 (+1.34%)

USD 4.00M
IDNA iShares Genomics Immunolo.. 0.00 % 0.00 %

+0.04 (+1.34%)

USD 0.12B
FYX:LSE 0.00 % 0.00 %

N/A

N/A
IBBJ 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 32.66% 81% B- 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 32.66% 81% B- 81% B-
Trailing 12 Months  
Capital Gain 26.65% 80% B- 79% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 26.65% 80% B- 78% C+
Trailing 5 Years  
Capital Gain 113.54% 90% A- 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 113.54% 90% A- 87% B+
Average Annual (5 Year Horizon)  
Capital Gain 55.23% 82% B 88% B+
Dividend Return 55.23% 82% B 88% B+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 161.18% 22% F 15% F
Risk Adjusted Return 34.27% 84% B 65% D
Market Capitalization 2.85B 77% C+ 83% B

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.